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different BDMARD, disenrollment from health insurance, reaching March 31, 
2011 or follow-up of 36 months. Exposure periods were subdivided into a 
quarterly (90-day) repeated-measures panel dataset. Within each quarter-panel, 
OGC use and rituximab adherence, measured using the proportion of days 
covered (PDC), were measured. Multivariable generalized estimating equation 
models examined the association between quarterly OGC use and prior quarter 
(lagged) PDC, adjusting for confounding variables. Multivariable-adjusted OGC 
use probabilities were predicted by PDC level (PDC=0 [i.e., reinfusion≥90 days 
late]; PDC=50 [reinfusion=45 days late]; PDC≥100 [reinfusion=on time/early]) 
using the G-computation method. RESULTS: Sample comprised 4,583 quarter-
panels (594 unique patients); mean age 55 years, 81% female. The multivariable-
adjusted OGC use probabilities decreased with time (p<0.001) and increasing PDC 
(p=0.006): from approximately 0.72 for all PDC levels in the first quarter-panel to 
0.64 (PDC=0), 0.55 (PDC=50), and 0.47 (PDC≥100) in the last (12th) quarter-panel. 
CONCLUSIONS: Increasing rituximab adherence was associated with statistically 
significant OGC use reduction over time.  
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ADHERENCE TO ORAL BISPHOSPHONATE THERAPY IN PATIENTS WITH 
OSTEOPOROSIS IN TIANJIN, CHINA  
Yu Q1, Wu J1, Wang D2, Liu J3, Jin L4 
1Tianjin University, Tianjin, China, 2Beijing Novartis Pharma Co., Ltd., Beijing, China, 3Tianjin 
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OBJECTIVES: To estimate the adherence to oral bisphosphonate medication use 
and its associated factors for patients with osteoporosis in Tianjin, China. 
METHODS: Data were obtained from the Tianjin Urban Employee Basic Medical 
Insurance (UEBMI) database (2008-2010) with 30% random selection. Patients 
with ≥ 1 osteoporosis diagnosis, aged 40 years and older, and who had ≥ 1 
pharmacy claim for oral bisphosphonate, including alendronate and etidronate, 
were selected. 12-month continuous enrollment before and after the first 
pharmacy claim for oral bisphosphonate were required. Adherence was 
measured with a medication possession ratio (MPR) and accounted for 6-month 
and 12-month. Multivariate logistic regression (MLR) analysis was conducted to 
assess the odds ratios (ORs) with 95% confidence intervals (CI) of potential 
confounding factors. RESULTS: A total of 918 patients with osteoporosis were 
identified with 64.9% female and a mean age of 64.7 (±10.4) years. The mean MPR 
was 0.24 (±0.25) and 0.13 (±0.15) at 6-month and 12-month follow-up period 
respectively. 96.62% of patients with MPR <50% and 81.05% of patients with MPR 
<20% were found in the 12-month analyses compared with 87.25% and 62.42% in 
the 6-month analysis respectively. During the first 6-month period, 48.69% of 
patients had only one bisphosphonate pharmacy claim and decreased to 47.82% 
when followed to 12-month. MLR results showed that patients with prior 
fractures during the study period may have better compliance (OR=3.15 and 
CI=1.23-8.10) while patients with coronary disease may have poorer compliance 
(OR=0.18 and CI=0.69-0.48) after adjusting for patients demographic and 
comorbidity characteristics. CONCLUSIONS: The adherence of oral 
bisphosphonate therapy for osteoporosis patients in Tianjin was significantly 
poorer compared to previous research in developed countries. More attentions 
should be paid and policy guidance is needed to improve the medication 
adherence among patients with osteoporosis in China.  
 
PMS46  
EVALUATING THE DIFFERENTIAL IMPACT OF PHYSICAL VERSUS MENTAL  
CO-MORBIDITIES ON THE HEALTH STATE UTILITIES OF PATIENTS WITH 
ARTHRITIS, ASTHMA, DIABETES AND MIGRAINE  
Rendas-Baum R, Miller K, Livote E, White MK 
Optum, Lincoln, RI, USA  
OBJECTIVES: To examine the differential impact of a physical versus a mental 
co-morbid condition on the health state utility (HSU) of patients with an existing 
physical condition. METHODS: Four base physical (B-Phys) conditions were 
examined: arthritis, asthma, diabetes and migraine. For each B-Phys, 5 physical 
co-morbidities (Co-Phys) were selected based on published clinical and 
epidemiologic studies; depression and anxiety were selected as the 2 mental co-
morbidities (Co-Mental). Mean HSUs (and 95% confidence intervals) were 
calculated for patients with only B-Phys and for patients with the B-Phys and 
either a Co-Phys or a Co-Mental. Data came from individuals (N=26,885) with one 
or two of the selected conditions who participated in the National Health and 
Wellness Study between 2007 and 2010. HSUs, calculated based on the SF-6D, 
were age- and gender-adjusted to reflect the mean age and gender composition 
of the sample. RESULTS: Patients with a Co-Phys had lower HSUs (mean 
differences ranged from -0.018 for asthma, to -0.061 for diabetes) when 
compared to patients with only B-Phys. However, these differences were 
substantially greater for subjects with a Co-Mental instead of a Co-Phys (mean 
differences ranged from -0.081 for asthma, to -0.093 for arthritis). The mean 
difference between the HSUs of patients with only the B-Phys and those of 
patients with both B-Phys and Co-Mental were between 1.4 (Diabetes) and 4.5 
(Asthma) times higher than the difference between patients with B-Phys and B-
Phys and Co-Phys. CONCLUSIONS: Economic evaluations of interventions are 
often based on published utilities among patients with a specific condition 
regardless of their other co-morbidities. Our results suggest that having a Co-
Mental has a substantially greater impact on HSUs than a Co-Phys. Studies 
aimed at evaluating interventions among patients with a particular condition 
must take into account the prevalence and type of co-morbidities among the 
population of interest.  
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RACE DIFFERENCES IN WALKING SPEED  
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OBJECTIVES: Physical function(PF) is an important determinant of health in the 
osteoarthritis (OA) population. Patient reported outcomes(PRO) are often used as 
primary endpoints for clinical research yet PROs measure attributes of PF that 
differ from performance-based measures [i.e., walking speed(WS)]. WS has been 
proposed as the “ sixth vital sign,” and a powerful predictor of health status and 
functional decline. The purpose of this study was to determine whether WS 
differs between community-dwelling African-American (AA) and White 
American (WA) adults with OA symptoms. METHODS: Participants were 1371 
individuals (27% African American) from the Osteoarthritis Initiative, a 
prospective observational cohort. Included individuals had both 1) ≥ 1 pain, 
aching, or stiffness in or around the knee on most days for at least 1 month 
during the past 12 months, and 2) the presence of osteophytes-grade 1. Linear 
regression models examined racial differences in WS adjusting for age, gender, 
education, body mass index (BMI), income, education, waist circumference, and 
comorbidities. RESULTS: WS was significantly slower for AA than WA, (mean 
speed 1.15m/s vs. 1.31m/s; p<0.001). Compared to the WA cohort, the AA cohort 
had more females (71% vs. 51%; p<0.001), were younger [mean age(SD) 60.0(8.5) 
vs. 61.9 (9.3); p<0.001], had a higher mean BMI [32.4(5.0)kg/m2 vs. 29.4(4.7) kg/m2; 
p<0.001], and lower income and education level. AAs had higher (p<0.001) 
prevalence of hypertension (18% vs. 10%), diabetes (23% vs. 7%), and rheumatoid 
arthritis (9.9% vs. 1.1%). Racial differences in WS persisted when controlling for 
age, gender, education, body mass index (BMI), income, education, waist 
circumference, and comorbidities (excluding RA). CONCLUSIONS: In this study, 
race is an independent predictor of WS. Establishing National Norms for WS by 
race and gender should be investigated before using WS as a health status 
measure and health outcome predictor.  
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QUALITY OF LIFE IN RHEUMATOID ARTHRITIS: HOW MUCH DO WE REALLY 
KNOW?  
Rolfe F, Kusel J, Brooks-Rooney C, Leonard SA 
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OBJECTIVES: Quality of life (QoL) is increasingly being included as a secondary 
endpoint in clinical trials, with reimbursement agencies requesting information 
on the wider impact of an intervention on the patient. The quality-adjusted life 
years (QALYs) used in cost-utility analyses take their weighting of life years 
gained with an intervention from the QoL scores calculated using utility 
instruments such as the EQ-5D. The question that this poses is, what precisely 
are such utility instruments measuring, and is this a good reflection of the 
improvements in health that society wishes to finance? The aim of this study 
was to use the case study of rheumatoid arthritis (RA) to demonstrate the extent 
to which clinical trials add to our understanding of the psycho-social QoL 
outcomes of an intervention, as opposed to pain and physical function. 
METHODS: All completed phase III/IV trials in RA with results listed on 
ClinicalTrials.gov were assessed for QoL outcomes and utility instrument used. 
The relative proportion of each instrument accounting for ‘psycho-social’ versus 
‘pain and physical function’, as defined by the SF-36 dimensions, was compared. 
RESULTS: Of the 76 studies analysed, 20 measured QoL (16 using SF-36, 2 using 
EQ-5D, 4 using both). The percentage of variance in each instrument attributable 
to pain and physical function versus psycho-social outcomes, as defined by SF-
36 dimensions, was applied to these results (EQ-5D: 88.8%=Pain and physical 
function, 11.2%=Psycho-social; SF-6D: 70.5%=Pain and physical function, 
29.5%=Psycho-social). It was found that only 24.5% of the QoL results available 
report on the psychosocial implications of the intervention. CONCLUSIONS: In 
conclusion, only a very small proportion of trials in this chronic condition 
measure the QoL outcomes of their interventions, and breaking down utility 
instruments into their component dimensions shows that only a small 
proportion of the total QoL outcomes reflect psycho-social implications.  
 
PMS49  
EMPIRICAL COMPARISON OF DISCRETE CHOICE EXPERIMENT AND BEST-
WORST SCALING TO ESTIMATE STAKEHOLDERS' RISK TOLERANCE FOR HIP 
REPLACEMENT SURGERY  
van Dijk JD1, Groothuis-Oudshoorn KG1, Marshall D2, IJzerman MJ1 
1University of Twente, Enschede, The Netherlands, 2University of Calgary, Calgary, AB, Canada  
OBJECTIVES: Empirical comparison of two preference elicitation methods, 
discrete choice experiment (DCE) and profile case best-worst scaling (BWS), 
regarding the estimation of the risk tolerance for hip replacement surgery (total 
hip arthroplasty and total hip resurfacing arthroplasty). METHODS: An online 
survey was constructed, following international guidelines, and consisted of 
socio-demographic questions and two randomised sections with 12 DCE and 8 
BWS questions. The survey was sent to a general population who can be faced 
with choosing between THA and TRA (males between 45-65 years old) in the US. 
After an intensive literature search, the following attributes were selected: 
probability of a first and a second revision in seven years, pain relief, ability to 
perform moderate daily activities, and hospital stay. In addition, survey 
respondents rated the difficulty of each method and the time to complete each 
section was monitored. BWS and DCE data was analysed using conditional logit 
analysis. The maximum acceptable risk (MAR) for a revision was estimated for 
four different hypothetical hip replacement scenarios. RESULTS: The final data 
set consisted of 429 respondents. The MARs estimated for four hypothetical hip 
replacement scenarios differed between both methods, ranging from 0% to 19% 
difference for a first revision. BWS questions took significantly more time (401 s.) 
than DCE (228 s.) questions. And respondents found BWS more difficult to 
complete. CONCLUSIONS: Both methods to elicit stakeholder preferences 
produce different results. Yet, both seem to be consistent in predicting risk 
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tolerance if the benefits are changed. However, DCE seems to be more sensitive 
for a change in benefits and risks while the MAR estimates obtained through 
BWS have considerably lower uncertainty than DCE.  
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RAPID IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH 
CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, 
INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL 
SPONDYLOARTHRITIS: 24-WEEK RESULTS OF A PHASE 3 DOUBLE BLIND 
RANDOMIZED PLACEBO-CONTROLLED STUDY  
Sieper J1, Kivitz A2, van Tubergen A3, Deodhar A4, Coteur G5, Woltering F6, Landewé R7 
1Univ Hospital Charité, Berlin, Germany, 2Altoona Center for Clinical Research, Duncansville, PA, 
USA, 3Maastricht University Medical Center, Maastricht, The Netherlands, 4Oregon Health and 
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OBJECTIVES: RAPID-axSpA (NCT01087762) investigated the impact of 
certolizumab pegol (CZP) on patient reported outcomes (PRO) in axial 
spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-
radiographic axSpA (nr-axSpA, axSpA with no definitive sacroiliitis on X-ray). 
METHODS: The ongoing 158-week (Wk) RAPID-axSpA trial was double blind and 
placebo-controlled to Wk24. Recruited patients had adult-onset active axSpA, 
including AS and nr-axSpA. Patients were randomized 1:1:1 to placebo, or 400mg 
CZP at Wk0, two and four followed by either 200mg CZP every two weeks (Q2W) 
or 400mg CZP every four weeks (Q4W). PRO endpoints included, physical 
function (BASFI), total spinal pain, daily pain diary to Wk4, fatigue (from 
BASDAI), Ankylosing Spondylitis Quality of Life (AsQoL), Sleep Problems Index II 
domain of the MOS Sleep scale, and SF-36. Change from baseline in PRO was 
analyzed in full analysis set with LOCF imputation. RESULTS: A total of 325 
patients were randomized. Baseline characteristics were similar between groups. 
Compared to placebo, improvements at Wk24 in CZP 200mg Q2W and 400mg 
Q4W treated groups were observed in pain (-1.3 vs. -3.3 and -3.2), fatigue (-0.9 vs. 
-2.6 and -2.8), BASFI (-0.5 vs. -2.4 and -2.2) and AsQoL (-1.7 vs. -5.1 and -5.1). 
Improvements were seen from Wk1, and in spinal pain from day 2. CZP-treated 
patients also had greater improvements in sleep, and SF-36 components and 
domains. More CZP patients reached population norms for SF-36. CZP impact on 
pain, fatigue and AsQoL in AS and nr-axSpA patients was similar. Relative to 
placebo, CZP-treated nr-axSpA patients demonstrated greater improvements in 
BASFI and sleep compared to AS, and were more likely to reach population 
norms for SF-36. CONCLUSIONS: Both dosing regimens of CZP rapidly improved 
all PRO including pain, fatigue, physical function and QoL of axSpA, in both AS 
and nr-axSpA patients.  
 
PMS51  
EFFECT OF CERTOLIZUMAB PEGOL ON THE MULTIPLE FACETS OF PSORIATIC 
ARTHRITIS AS REPORTED BY PATIENTS: 24-WEEK PATIENT REPORTED 
OUTCOME RESULTS OF A PHASE 3 DOUBLE BLIND RANDOMIZED PLACEBO-
CONTROLLED STUDY  
Gladman D1, Fleischmann R2, Coteur G3, Woltering F4, Mease P5 
1University of Toronto, Toronto, ON, Canada, 2Metroplex Clinical Research Center, Dallas, TX, 
USA, 3UCB Pharma, Brussels, Belgium, 4UCB Pharma, Monheim, Germany, 5Swedish Medical 
Center, Seattle, WA, USA  
OBJECTIVES: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient reported outcomes (PRO) in psoriatic arthritis (PsA), as 
investigated in RAPID-PsA (NCT01087788). METHODS: The ongoing 158 week 
(Wk) RAPID-PsA trial is double blind and placebo-controlled to Wk24. Recruited 
patients had active PsA and had failed ≥1 DMARD. Patients could have received 1 
previous anti-TNF. Patients were randomized 1:1:1 to placebo, or 400mg CZP  
at Wk 0, 2 and 4 (loading dose) followed by either 200mg CZP every 2 weeks 
(Q2W) or 400mg CZP every 4 weeks (Q4W). PRO measures evaluated: fatigue 
assessment scale (FAS), patient assessment of pain (VAS), health assessment 
questionnaire-disability index (HAQ-DI), SF-36, PsAQoL, and the Dermatology 
Life Quality Index (DLQI). Change from baseline for PRO was analyzed for  
the randomized population, with LOCF imputation. RESULTS: A total of 409 
patients were randomized. 20% of patients had received a prior anti-TNF. 
Baseline demographics were similar between groups. From baseline to Wk24, 
differences in pain (-11.2 vs. -28.6 and -28.4), fatigue (-0.6 vs. -2.2 and -1.9), HAQ-
DI (-0.19 vs. -0.54 and -0.46), SF-36 physical component summary (2.14 vs. 8.43 
and 7.58) and mental component summary (0.73 vs 5.49 and 3.49), PsAQoL (-1.27 
vs. -4.43 and -3.30), and DLQI (-1.4 vs. -6.3 and -5.2) were observed in placebo vs. 
CZP 200mg Q2W and 400mg Q4W arms (p<0.001). Differences were observed 
from Wk1 and were irrespective of prior anti-TNF exposure. More patients on 
CZP reached SF-36 general population norms than placebo patients. 
CONCLUSIONS: CZP effectively improved multiple PROs in PsA patients across 
many disease facets. The benefits of CZP treatment on physical and emotional 
components of HRQoL were seen across generic, PsA-specific and dermatology-
specific measures. These benefits were seen in patients regardless of prior anti-
TNF exposure.  
 
PMS52  
THE IMPORTANCE OF MANAGING ARTHRITIS IN PATIENTS WITH BOTH 
MODERATE-TO-SEVERE PSORIASIS AND PSORIATIC ARTHRITIS  
Kirkham B1, Boggs R2, Li W2, Nab HW3, Tarallo M3 
1Guy’s and St Thomas’ NHS Foundation Trust, London, UK, 2Pfizer Inc, Collegeville, PA, USA, 
3Pfizer Italia, Rome, Italy  
OBJECTIVES: To determine the impact of improvements in skin and 
musculoskeletal components on quality of life (QoL), we studied patients with 
both moderate-to-severe psoriasis and psoriatic arthritis (PsA) treated with 
etanercept (ETN). METHODS: Ad hoc analyses were performed on pooled data 
from the PRESTA trial in which patients were randomized to ETN 50 mg once 
weekly (QW) for 12 weeks or ETN 50 mg twice weekly for 12 weeks, followed by 
ETN 50 mg QW for 12 weeks. Dermatologists evaluated skin disease using the 
Psoriasis Activity and Severity Index (PASI) endpoints PASI50 (50% improvement) 
and PASI75 (75% improvement). Rheumatologists evaluated arthritis using the 
American College of Rheumatology (ACR) endpoints of ACR20 and ACR50 (≥20% 
and ≥50% improvement in ACR core criteria, respectively). To measure QoL, 
patients completed the EuroQoL-5 Dimension (EQ-5D) utility (scale 0–1, higher 
scores=better QoL, minimal important difference [MID]=0.05) and Visual Analog 
Scale (VAS; scale 0–100, higher scores=better health state, MID=5) questionnaire. 
RESULTS: Improvements from baseline at week 24 in EQ-5D utility and VAS 
scores for patients achieving ACR50 but not PASI75 (n=89) were significantly and 
clinically meaningfully greater than patients achieving PASI75 but not ACR50 
(n=193; EQ-5D utility Δ=0.327 vs. 0.199, P<0.001; EQ-5D VAS Δ=23.7 vs. 15.1, 
P=0.002). Similarly, improvements for patients achieving ACR20 but not PASI50 
(n=55) were significantly greater than those achieving PASI50 but not ACR20 
(n=163; EQ-5D utility Δ=0.385 vs. 0.134, P<0.001; EQ-5D VAS Δ=19.3 vs. 10.4, 
P=0.005). CONCLUSIONS: Patients with both moderate-to-severe psoriasis and 
PsA showing greater improvements in arthritis than psoriasis reported more QoL 
gains compared with those with greater improvements in psoriasis than 
arthritis. Although the ACR response and PASI measures are formed of different 
components, the magnitude of the QoL gain with improvement in arthritis 
shows that the arthritis component of psoriatic disease contributes significantly 
to reduced QoL.  
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IMPACT OF RHEUMATOID ARTHRITIS (RA) ON QUALITY OF LIFE (QOL) IN A 
NATIONALLY REPRESENTATIVE POPULATION IN THE UNITED STATES  
Kavati A1, Rappaport H2 
1Philips Healthcare, Andover, MA, USA, 2University of Louisiana at Monroe, Monroe, LA, USA  
OBJECTIVES: To assess the physical component score (PCS), mental component 
score (MCS), and EuroQol (EQ5D) score of RA and non-RA patients. METHODS: 
Retrospective analysis of civilian non-institutionalized Medical Expenditures 
Panel Survey (MEPS) data for the year 2006. 20,434 respondents had positive 
weight, had complete information, and who were atleast 18 years were included 
in the analysis. Clinical Classification Code 202 identified RA respondents. RA 
and Non-RA respondents were matched on age, gender, race, education, marital 
status, income, region, insurance, and comorbidity index score. Since the MEPS 
2006 consists of only PCS and MCS, a mapping algorithm was used to derive EQ-
5D score. Proc surveyfreq, and proc surveymeans to describe the demographic 
characteristics. T-tests were used to measure statistical differences in QOL 
scores between the 2 groups. RESULTS: Among adults with RA, 86.75% were 
whites with mean (SE) age of 59.83 (1.18) years and 80% were females. The mean 
(SE) PCS scores for the RA and Non-RA group was 34.25 (1.35) and 45.46 (1.30). 
The mean (SE) MCS scores for the RA and Non-RA group was 47.49 (1.09) and 
51.14 (0.86). The mean (SE) EQ-5D index score for the RA and Non-RA groups was 
0.74 (0.02) and 0.86 (0.01). The results were significant at an apriori alpha value of 
0.05. CONCLUSIONS: Since the disease conditions were self-reported and 
institutionalized persons were not included, the true prevalence of RA may be 
underestimated. All QOL scores for RA patients were lower in the 2006 MEPS data 
indicating that respondents with RA have reduced QOL. RA significantly impairs 
QOL in the U.S. population. The study trengthens the importance of treating RA. 
This study did not differentiate QOL by severity of RA. RA-specific QOL measures 
were unavailable in MEPS.  
 
PMS54  
USTEKINUMAB IMPROVES ARTHRITIS-RELATED AND SKIN-RELATED QUALITY 
OF LIFE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: PATIENT 
REPORTED OUTCOMES FROM RANDOMIZED AND DOUBLE BLINDED PHASE III 
PSUMMIT I TRIAL  
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Han C8, Mendelsohn A9, Doyle M7 
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OBJECTIVES: Examine impact of ustekinumab treatment on general &disease-
specific patient reported outcomes (PROs) of patients with active PsA using 
PSUMMIT1 data. METHODS: Adult PsA patients (n=615) with active disease 
despite DMARD&/or NSAID therapy were randomized to ustekinumab 45mg, 
90mg, or PBO at wks0, 4, &q12wks, thereafter. Patients treated with prior anti-
TNF agents were excluded. At wk16, patients with <5% improvement in SJC/TJC 
entered blinded EE (PBO→ustekinumab 45mg; ustekinumab 45mg→90mg; 
90mg→90mg). PROs were measured with HAQ, DLQI, SF-36, &VAS for impact of 
PsA on work productivity (0-10), patient assessment of pain (0-10)& disease 
activity (0-10). ANOVA on van der Waerden normal scores was used for 
continuous variables & chi-square or the Cochran-Mantel-Haenszel (CMH) test 
for binary variables between groups. RESULTS: Baseline PRO measures indicated 
the study population had severe physical disability& impaired HRQoL, with 
mean HAQ score of 1.25 &mean DLQI score of ≥10. At wk24, greater 
improvements in: HAQ (0.31&0.4 vs. 0.1, P<0.001), DLQI (6.6&7.5 vs. 1.4, P<0.001), 
SF-36 PCS (4.9 &6.2 vs. 1.4, P<0.001)& MCS (3.4&4.8 vs. 1.5, p<0.01 90 mg only) 
were observed in ustekinumab 45mg &90mg groups vs PBO, respectively. 
Proportions of patients who achieved clinical meaningful improvements in HAQ 
≥0.3 (47.8% &47.5% vs. 28.2%, P<0.001), DLQI ≥5 (58.6% &63.1% vs. 32.9%, P<0.001), 
&SF-36 PCS ≥5(46.5% &53.3% vs. 26.0%, P<0.001) &MCS ≥5(37.0% &47.7% vs. 33.7%, 
p<0.01 90mg only) were greater in ustekinumab 45mg &90mg group vs PBO, 
